Nitral

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitral

Nitral: An Overview of Its Identity and Therapeutic Role

Property Description
Active Ingredient Glyceryl Trinitrate (Nitroglycerin)
Primary Form Sublingual Tablet
Pharmacological Class Organic Nitrate, Systemic Vasodilator
General Purpose Management of Angina Pectoris (Chest Pain)
Origin Synthetic Chemical Compound

What Is Nitral and What Class of Medicine Is It?

Nitral is a prescription medication whose active component is Glyceryl Trinitrate, a synthetic compound classified as an organic nitrate and systemic vasodilator. The primary medical action of this class of drugs is to promote the widening of blood vessels.

The medicine is most commonly encountered as a small, oral sublingual tablet, designed for rapid absorption under the tongue, though it is also available in transdermal patches for longer-term therapy. This medication is utilized for treating conditions where blood flow is restricted, helping the heart by improving blood delivery throughout the body.

Is Nitral Natural, Synthetic, or Derived?

Glyceryl Trinitrate, the compound in Nitral, is a purely synthetic chemical compound, created in a laboratory setting to achieve precise purity and stability for therapeutic use. Chemically defined as a nitrate ester, it is produced through an industrial synthesis process and is not sourced from a plant or natural biological organism.

Its synthetic origin is vital for a drug that must act rapidly and predictably in acute cardiac situations, ensuring dependable therapeutic effects that might not be possible with naturally extracted substances.

What Condition Does Nitral Generally Target?

Nitral's overarching therapeutic purpose is the immediate relief and preventive management of angina pectoris, which is the acute chest pain resulting from insufficient blood flow to the heart muscle. It is a primary medication used when a patient experiences sudden, crushing chest pain due to an underlying heart condition.

The drug works by quickly causing vasodilation, which in turn reduces the workload on the heart and restores adequate oxygen supply to the affected tissue. Nitrate administration serves to quickly ease anginal discomfort by improving circulation when the heart is strained.

Regulatory References

  1. MedlinePlus notes

What side effects are possible with Nitral?

Nitral: Possible side effects and safety information

The safety profile of Nitral (Glyceryl Trinitrate) is officially structured by its potential impact on several physiological systems, with adverse reactions categorized by frequency as defined in regulatory documents. The most Very Common official adverse reaction is headache, which is generally reported to be more likely at the start of treatment and may diminish with continued use. Other Common reactions include dizziness, orthostatic hypotension (a drop in blood pressure upon standing), tachycardia (increased heart rate), asthenia (weakness), and somnolence (drowsiness).


Adverse effects are documented across various System-Organ Classes, including the Nervous System, Vascular System, and Cardiac System. Uncommon reactions may involve nausea, vomiting, and, importantly, circulatory collapse (which can be accompanied by syncope). A critical safety constraint officially mandated in regulatory labeling is the risk of severe hypotension and life-threatening circulatory collapse if this medicine is used concomitantly with Phosphodiesterase Type 5 (PDE-5) inhibitors.


Specific safety considerations exist for certain populations, as mandated by official labels. Regulatory documents state that the safety and effectiveness of the medicine have not been established in the pediatric population (under 18 years). Furthermore, caution is officially advised in individuals with severe hepatic or renal impairment due to the potential for altered drug clearance. Continued, chronic use is officially noted to be associated with the development of drug tolerance.

Overdose and Emergency Response

The official documentation for Nitral (Glyceryl Trinitrate) defines overdose based on the pronounced effects of excessive vasodilation. Overdose may present with severe cardiovascular manifestations including profound hypotension, circulatory collapse, and disturbances such as reflex tachycardia or paradoxical bradycardia. Neurological signs are also documented, including a persistent throbbing headache, confusion, vertigo, and, in severe cases, seizures or coma. A critical outcome noted in regulatory labeling is Methaemoglobinaemia, which requires attention and is often visible as cyanosis (bluish coloration of the skin or lips).

The regulatory mandate is to seek immediate medical attention for any suspected overdose. Specifically, official guidance states that emergency medical help must be sought if chest pain persists after the use of three doses/tablets within a 15-minute period, or if severe signs such as collapse or inability to be awakened occur.

Overdose management, as officially described, is symptomatic and supportive. Treatment involves measures like limb elevation and rapid volume replacement using intravenous fluids to counteract hypotension. While no specific antidote is known for the overdose itself, Methylene blue or Vitamin C are documented treatments for Methaemoglobinaemia. It is explicitly noted in official labeling that epinephrine is contra-indicated for treating severe hypotension related to this overdose.

Therapeutic Uses of Nitral

What Nitral Treats: Main Uses and Benefits

Nitral is used to treat episodes of angina (chest pain) in people who have coronary artery disease. This medication is commonly used to provide supportive symptomatic relief when a patient experiences acute angina pectoris, which is the sudden, intense squeezing or pressure in the chest. It is applied in addressing the pronounced, often radiating pain associated with insufficient blood flow, offering essential support that helps ease the immediate discomfort and may assist with easing the duration or distress of the episode.

Nitral is considered relevant for prophylactic management in individuals with recurrent, stable angina. This use is applicable in situations where patients anticipate triggers, such as physical exertion or emotional tension, that generally cause their symptoms. This medication is applicable within clinical settings that involve symptomatic relief for coronary artery disease, acute coronary syndromes (as adjunctive management of pain), and stable angina.

“The medication is commonly used when symptoms intensify and supportive relief is needed, helping to address symptom clusters that may become intense or disruptive.”

Applying the medication preemptively may assist with managing the severity or occurrence of expected episodes, thereby contributing to easing the overall symptom load and supports functional stability. In broader clinical contexts, it assists in the adjunctive management of symptom burden during phases marked by heightened patient distress, and can provide temporary assistance in symptom stabilization.


Quick Fact: Relief for Acute Chest Discomfort The primary use of this medication is to provide supportive relief for sudden, acute episodes of chest pain and associated pressure, helping patients cope more steadily with symptom fluctuations.

Regulatory References

  1. Nitroglycerin Spray is used to treat episodes of angina (chest pain) in people who have coronary artery disease

Eligibility and Restrictions for Use

The official eligibility profile for Nitral (Glyceryl Trinitrate) establishes clear limits on who can and cannot use the medicine. It is absolutely contraindicated in patients with a known hypersensitivity to the drug or other organic nitrates. Use is strictly prohibited in individuals with severe anemia or conditions causing increased intracranial pressure. A critical contraindication involves the concurrent use of Phosphodiesterase-5 (PDE-5) inhibitors (like sildenafil) or soluble guanylate cyclase (sGC) stimulators (like riociguat). The medicine is established for use in adults (18 years and older), but safety and effectiveness have not been established in pediatric patients (under 18 years), and use is not recommended for this age group. Caution is required for older adults due to the higher probability of age-related organ issues. Use during pregnancy and lactation is conditional and requires a risk-benefit assessment due to limited human data, and caution is also mandated for patients who are hypotensive or have specific heart valve conditions (e.g., aortic stenosis).

What should I know about interactions with other medicines?

The official interaction profile for Nitral (Glyceryl Trinitrate) is defined by agents that significantly enhance its blood pressure-lowering effects. Regulatory documents structure this profile primarily around mandatory prohibitions based on pharmacodynamic reinforcement.


Interaction Restrictions and Contraindications

Agent Category Interaction Type Regulatory Restriction
Phosphodiesterase Type 5 (PDE5) Inhibitors (e.g., Sildenafil, Tadalafil) Pharmacodynamic Reinforcement Contraindicated Combination
Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat) Pharmacodynamic Reinforcement Contraindicated Combination

Co-administration with all PDE5 Inhibitors and sGC Stimulators is formally prohibited across government regulatory documents. This is due to the documented risk of severe, life-threatening hypotension and circulatory collapse, which constitutes a primary constraint on use.


Other Clinically Significant Interactions

Other medicinal products that lower blood pressure, such as beta-blockers, calcium channel blockers, diuretics, and ACE inhibitors, may result in an additive pharmacodynamic effect. This effect enhances the documented risk of systemic hypotension when these agents are co-administered. No specific timing separation rules are mandated for these combinations in regulatory labeling.

Substance-Specific Interaction

The ingestion of alcohol (ethanol) is documented to potentiate the vasodilating and hypotensive effects of the drug. The regulatory documents emphasize these defined interaction categories and associated constraints.

Mechanism of Action

How Nitral Works

The action of Nitral (Glyceryl Trinitrate) involves the modulation of vascular smooth muscle tone via the Nitric Oxide ( NO) signaling pathway. Its mechanism involves an enzyme-dependent bioactivation followed by the initiation of an intracellular messenger system.

Molecular Bioactivation and NO Release

The drug functions as a prodrug that requires an enzymatic conversion process, primarily involving the Mitochondrial Aldehyde Dehydrogenase 2 ( ALDH2) enzyme, to become active. This interaction liberates the gaseous signaling molecule, Nitric Oxide ( NO), within the vessel wall. The release of NO is the initial step, and the quantity generated directly determines the magnitude of the subsequent smooth muscle relaxation.

Activation of the cGMP Pathway and Vasodilation

The released NO activates its main downstream target, the enzyme Soluble Guanylate Cyclase ( sGC), leading to a surge in the secondary messenger, cyclic Guanosine Monophosphate ( cGMP). Elevated cGMP levels trigger a cascade that deactivates the contractile elements within the vascular smooth muscle cells, causing widespread relaxation and vasodilation in both arteries and veins.

Reduction of Cardiac Preload (Systemic Effect)

The cGMP-induced smooth muscle relaxation shows a strong preference for the peripheral veins (capacitance vessels). This venodilation causes blood to pool away from the heart, leading to a reduction in the volume and pressure of blood returning to the heart (preload). This core physiological consequence reduces the overall mechanical demand on the heart muscle.

Dosage and Administration Information

Official Administration Guidelines for Nitral

Nitral (Glyceryl Trinitrate) is administered via specific protocols based on its formulation. These instructions are designed to ensure the correct delivery and schedule are followed.


Administration Routes and Dosing

The medicine is approved for sublingual (under the tongue), transdermal (skin patch), and intravenous (continuous hospital infusion) routes.

Feature Acute Use (Sublingual Tablet/Spray) Chronic Use (Transdermal Patch)
Route of Administration Sublingual or Buccal Transdermal (on skin)
Standard Dosing One dose (tablet or spray) at the onset. Applied once daily (e.g., 0.2 mg/hr to 0.8 mg/hr systems).
Frequency Limit May repeat every 5 minutes. Maximum of 3 doses within a 15-minute period. Daily application with a required patch-free interval.
Prophylactic Use Administered 5 to 10 minutes prior to activities likely to precipitate an episode. Not applicable for acute relief.

Special Procedural and Timing Requirements

Acute Forms: Standard administration protocols specify that the patient should rest (ideally sitting) during acute administration. Sublingual tablets must be allowed to dissolve without being chewed, crushed, or swallowed. Lingual sprays should be administered onto or under the tongue and not inhaled.

Transdermal Forms: To prevent the development of tolerance, an intermittent regimen is utilized. The patch is typically removed daily to ensure a mandatory 10 to 12-hour drug-free interval. This cycling is essential for maintaining efficacy during long-term preventive therapy.

Specific Populations: Dosing for older adults is generally approached with caution, typically starting at the lower end of the established range.

These protocols define the precise, time-restricted sequence for episodic use and the necessary cyclical regimen for long-term preventive administration.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Nitral (Glyceryl Trinitrate)

This section provides an overview of the research base for Nitral, focusing on the types of clinical studies and official regulatory evidence that describe its use, without offering any clinical guidance or recommendations.


Evidence for Use in Acute Angina Pectoris (Rapid Relief)

The primary use of Nitral was studied for its application during acute episodes of chest pain. The evidence relies on physiological and pharmacological studies, alongside older controlled efficacy trials. Researchers examined outcomes related to physical discomfort, such as the time required for the patient to report a change in acute chest pain or pressure. Studies observed patterns where patients reported that symptoms evolved quickly following administration.

Evidence for Prophylactic Management of Stable Angina

Research has explored the use of Nitral preemptively, where it was studied for preventing or delaying symptoms when a patient anticipates triggers like physical exertion. Studies often use rigorous crossover trials and exercise tolerance testing. Controlled activity studies observed patterns related to the duration of activity before the onset of symptomatic or objective signs of angina. The research base accounts for nitrate tolerance, a phenomenon where the body's response to continuous use may be altered, making the study of sustained effect a key focus.


Research Gaps and Remaining Uncertainties

Evidence quality varies across studies, especially those looking at long-term endpoints. Long-term effects are not fully established, particularly concerning its impact on mortality or reinfarction rates over several years. Data regarding major long-term endpoints is inconsistent and often conflicting. Furthermore, research is limited in providing clear insight for certain groups, such as those with complex or multiple concurrent cardiac conditions, and the results apply only to the adult populations studied in the major trials.

Key Studies & References

  1. Nitroglycerin Sublingual: MedlinePlus Drug Information
  2. Nitroglycerin Spray: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Nitral (FAQ)


Q: Are there any specific foods or drinks to avoid while using Nitral?

Regulatory documents state that alcohol is advised against when using this medicine, as it can significantly increase the documented risk of low blood pressure. No other specific foods are generally listed as mandatory to avoid in the official product information. A healthcare provider can offer guidance on specific dietary concerns.


Q: What are the most common reasons someone might have to stop taking Nitral?

According to the official product information, certain formal contraindications may represent conditions where the medicine is formally contraindicated. These include having severe anemia or increased intracranial pressure. Additionally, if a patient experiences severe low blood pressure (hypotension), regulatory documents indicate discontinuation may be necessary.


Q: What is the risk of having a serious side effect with Nitral?

The official labels note that most side effects are common and temporary, like headaches. However, rare, serious side effects can occur, including severe hypotension (a dangerous drop in blood pressure) which can lead to syncope (fainting) or circulatory collapse. The frequency of these serious events is officially classified as uncommon or rare in regulatory documents.


Q: Can Nitral cause changes in mood or sleep?

Official information indicates that common side effects include drowsiness (somnolence) and dizziness, which are related to alertness and sleep patterns. Changes in mood are not typically listed in the official adverse reaction profiles for this medicine.


Q: What are the signs of an allergic reaction to Nitral?

Hypersensitivity (a severe allergy) to the drug is a formal contraindication for use. While rare, signs of an allergic reaction can include typical symptoms such as hives or rash, itching, or swelling of the face, lips, or tongue.


Q: Is it safe to drive or operate machinery while on Nitral?

The official patient information advises caution because this medicine may affect your alertness or coordination. Due to the documented risk of dizziness or fainting, official patient information advises caution regarding driving or operating complex machinery until the patient understands the effects of the medication.


Q: Can a patient with a history of heart problems use Nitral?

Official documents list specific heart-related conditions that contraindicate use, such as very recent heart attack or hypertrophic obstructive cardiomyopathy (a heart muscle disease). Caution is also advised if a patient has low blood pressure. Eligibility is generally determined by a healthcare provider after evaluating a patient's full cardiac history.


Q: How is Nitral eliminated from the body?

According to the official clinical pharmacology information, the primary route of elimination is through metabolism (breakdown) within the body. The drug is eliminated from the bloodstream very rapidly after it has been absorbed.


Q: How quickly should I expect Nitral to start working?

Studies and official information indicate that the sublingual tablet form is rapidly absorbed into the bloodstream. Regulatory documents note that relief is typically rapid, often expected within the first 5 minutes of the first dose for acute symptoms.


Q: How long does one dose of Nitral typically last in the body?

The medicine is cleared from the bloodstream very rapidly. Official pharmacokinetic data states that the mean elimination half-life (the time it takes for half the drug to be eliminated) is approximately 2 to 3 minutes.


Q: Can Nitral be taken with pain relievers like ibuprofen or aspirin?

Regulatory sources suggest that some nonprescription products, such as aspirin, may interact with nitroglycerin. A healthcare provider should be consulted about the use of any non-prescription pain relievers.


Q: Is it okay to drink coffee or caffeine while taking Nitral?

There are no documented interactions between nitroglycerin and common non-alcoholic drinks, including caffeine, noted on the regulatory labels. Alcohol, however, is formally documented as an interaction to be avoided due to the documented risk of severe low blood pressure.


Q: Why do official documents mention [specific lab test name] when describing Nitral use?

Official documents discuss the risk of methemoglobinemia (a blood condition) with overdose or high exposure to the medicine. This is a condition that requires laboratory testing, specifically by measuring methemoglobin levels, to be diagnosed.


Q: Is Nitral a controlled substance?

No, Nitral is not listed as a controlled substance in the official regulatory categorization. It is classified as a prescription-only drug, designated as 'Rx only.'


Q: Do I need to take Nitral with food?

The sublingual form is specifically designed to dissolve under the tongue or between the cheek and gum. Regulatory documents describe the sublingual form as requiring patients to avoid eating or drinking while the tablet is dissolving.


Q: Are there certain supplements or vitamins that should not be combined with Nitral?

Official patient information states that new supplements, vitamins, or herbal remedies should be discussed with a healthcare provider. Grapefruit juice has also been specifically noted in regulatory documentation as an interaction to avoid.


Q: Is the generic version of Nitral the same as the brand name?

Nitral is a brand name for the generic drug nitroglycerin (Glyceryl Trinitrate). Both the generic and brand-name formulations contain the same active medicinal ingredient.


Q: What should I do if my symptoms get worse while taking Nitral?

Official documents direct that if chest pain persists after the maximum recommended number of doses within a specified time period (e.g., three tablets in 15 minutes), or if the pain feels different or unusually severe, prompt medical attention is directed.


Q: Can Nitral interact with herbal remedies like St. John's Wort?

Regulatory documents note that new herbal remedies should be discussed with a healthcare provider. This precaution covers all herbal products due to the potential for unknown drug interactions.


Q: What happens when you stop taking Nitral?

For individuals who have been on continuous or high-dose therapy, official warnings note that the sudden withdrawal of the drug may lead to symptoms like increased chest pain. In rare cases, physical dependence has been noted in occupational settings, which may necessitate medical supervision upon discontinuation.


Q: Are there different strengths of Nitral available?

Yes, regulatory documents indicate that the sublingual tablets are supplied in multiple strengths, such as 0.3 mg, 0.4 mg, and 0.6 mg doses. Other forms like transdermal patches and sprays are also manufactured in various strengths.


Q: Does Nitral contain any ingredients that cause problems for people with common allergies (like lactose or gluten)?

Various formulations may contain common inactive ingredients (excipients), such as lactose monohydrate, which could be relevant to certain allergies. Patients with known allergens should review the specific ingredient list for their prescribed formulation with their pharmacist.

How should Nitral be stored and disposed of?

Storage Requirements

Nitral (Glyceryl Trinitrate) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). Storage conditions are explicitly required to protect the medicine from light and moisture, and the product must not be frozen.

The medication must be kept in its original container and the container must remain tightly closed when not in use. Stability is guaranteed only when the labeled storage conditions are strictly followed, and the product must be discarded after its expiration date.

Disposal and Safety

It is mandatory to keep Nitral out of the reach of children. Unused or expired product must be disposed of using a drug take-back program or by mixing the medicine with an undesirable substance before discarding it in the household trash. The medicine must not be flushed down the toilet or poured down the sink, according to official disposal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nitral found in:

A-Z Index: